Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin

被引:19
作者
Crook, D
机构
[1] Wynn Division of Metabolic Medicine, Imperial College School of Medicine, National Heart and Lung Institute, London
[2] Wynn Division of Metabolic Medicine, Imperial College School of Medicine, National Heart and Lung Institute, London
关键词
oral contraceptives; desogestrel; gonadotrophins; estradiol; progesterone; thyroid function;
D O I
10.1016/S0010-7824(97)00010-3
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
We assessed endocrine function and plasma lipid and lipoprotein concentrations in 112 women given a monophasic oral contraceptive containing 30 mu g ethinyl estradiol and 150 mu g desogestrel. These women were participating in a larger trial of cycle control and safety. Plasma concentrations of gonadotrophins, estradiol, and progesterone fell over the 18 months of this study, consistent with suppression of the hypothalamic-pituitary-ovarian (HPO) axis. There was no consistent effect on plasma prolactin concentrations. Concentrations of total triiodothyronine, thyroxine, and cortisol increased, tracking increases in their binding proteins. Within 6 months, plasma total cholesterol concentrations had increased by 12% (p < 0.001) with no effect on those of low density lipoproteins. Concentrations of triglycerides and high-density lipoprotein cholesterol increased by 79% and 14%, respec tively (both p < 0.002). Monophasic ethinyl estradiol/desogestrel effectively suppressed the HPO axis. Other endocrine changes were typical of oral contraceptives containing ethinyl estradiol. The increase in triglyceride concentrations is not considered to increase cardiovascular risk, whereas the increase in high-density lipoproteins may be protective. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:219 / 224
页数:6
相关论文
共 28 条
[1]   EFFECTS OF ORAL-CONTRACEPTIVE STEROIDS ON PITUITARY PROLACTIN SECRETION [J].
ABUFADIL, S ;
DEVANE, G ;
SILER, TM ;
YEN, SSC .
CONTRACEPTION, 1976, 13 (01) :79-85
[2]   ASSOCIATIONS OF SERUM-LIPID CONCENTRATIONS AND OBESITY WITH MORTALITY IN WOMEN - 20 YEAR FOLLOW-UP OF PARTICIPANTS IN PROSPECTIVE POPULATION STUDY IN GOTHENBURG, SWEDEN [J].
BENGTSSON, C ;
BJORKELUND, C ;
LAPIDUS, L ;
LISSNER, L .
BMJ-BRITISH MEDICAL JOURNAL, 1993, 307 (6916) :1385-1388
[3]   LIPID-METABOLISM EFFECTS WITH DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVES [J].
BURKMAN, RT .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (03) :1033-1040
[4]   ORAL-CONTRACEPTIVES AND CORONARY HEART-DISEASE - MODULATION OF GLUCOSE-TOLERANCE AND PLASMA-LIPID RISK-FACTORS BY PROGESTINS [J].
CROOK, D ;
GODSLAND, IF ;
WYNN, V .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 158 (06) :1612-1620
[5]   ANDROGENIC, ANABOLIC, ESTROGENIC AND ANTIESTROGENIC EFFECTS OF DESOGESTREL AND LYNESTRENOL - EFFECTS ON SERUM-PROTEINS AND VAGINAL CYTOLOGY [J].
CULLBERG, G .
CONTRACEPTION, 1984, 30 (01) :73-79
[6]   INFLUENCE OF ORAL-CONTRACEPTIVES ON INTEGRATED SECRETION OF GONADOTROPINS [J].
DERICKSTAN, JSE ;
GUDACKER, V ;
TAUBERT, HD .
CONTRACEPTION, 1992, 46 (04) :369-377
[7]   12 YEARS OF CLINICAL-EXPERIENCE WITH AN ORAL-CONTRACEPTIVE CONTAINING 30-MU-G ETHINYLESTRADIOL AND 150-MU-G DESOGESTREL [J].
FOTHERBY, K .
CONTRACEPTION, 1995, 51 (01) :3-12
[8]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[9]   PLASMA-HORMONE LEVELS IN WOMEN RECEIVING NEW ORAL-CONTRACEPTIVES CONTAINING ETHINYL ESTRADIOL PLUS LEVONORGESTREL OR DESOGESTREL [J].
GASPARD, UJ ;
ROMUS, MA ;
GILLAIN, D ;
DUVIVIER, J ;
DEMEYPONSART, E ;
FRANCHIMONT, P .
CONTRACEPTION, 1983, 27 (06) :577-590
[10]   THE EFFECTS OF DIFFERENT FORMULATIONS OF ORAL-CONTRACEPTIVE AGENTS ON LIPID AND CARBOHYDRATE-METABOLISM [J].
GODSLAND, IF ;
CROOK, D ;
SIMPSON, R ;
PROUDLER, T ;
FELTON, C ;
LEES, B ;
ANYAOKU, V ;
DEVENPORT, M ;
WYNN, V .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (20) :1375-1381